April 19, 2018 09:35 AM EDT
Financing

In knock­out IPO of­fer­ings, Mor­phoSys and Sur­face On­col­o­gy haul com­bined $316M in up­sized deals

Brittany Meiling

Two biotechs new to Nas­daq sparked more in­vestor in­ter­est than orig­i­nal­ly ex­pect­ed Wednes­day, haul­ing up­sized IPOs that are yet an­oth­er in­di­ca­tion of the in­dus­try’s rip …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times